Dr. Ajay K. Nooka, MD,MPH,FACP
Claim this profileEmory Winship Cancer Institute
Studies Multiple Myeloma
Studies Plasma Cell Neoplasm
8 reported clinical trials
12 drugs studied
Area of expertise
1Multiple Myeloma
t(4;14) positive
del(17p) positive
t(14;16) positive
2Plasma Cell Neoplasm
t(4;14) positive
del(17p) positive
t(14;16) positive
Affiliated Hospitals
Clinical Trials Ajay K. Nooka, MD,MPH,FACP is currently running
Belantamab Mafodotin + Pomalidomide + Dexamethasone
for Multiple Myeloma
This phase II trial studies the effect of belantamab mafodotin, pomalidomide, and dexamethasone in treating patents with high-risk myeloma. Belantamab mafodotin is a monoclonal antibody, called belantamab, linked to a chemotherapy drug, called mafodotin. Belantamab is a form of targeted therapy because it attaches to specific molecules on the surface of cancer cells, known as BCMA receptors, and delivers mafodotin to kill them. Chemotherapy drugs, such as pomalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Giving belantamab mafodotin, pomalidomide, and dexamethasone may kill more cancer cells.
Recruiting1 award Phase 218 criteria
Belantamab Mafodotin Combinations
for Multiple Myeloma
B-cell maturation antigen (BCMA) is a target present on tumor cells in participants with multiple myeloma. Belantamab mafodotin (GSK2857916); is an antibody-drug conjugate (ADC) containing humanized anti-BCMA monoclonal antibody (mAb). This is a phase I/II, randomized, open-label, platform study designed to evaluate the effects of belantamab mafodotin in combination with other anti-cancer drugs in participants with relapsed/refractory multiple myeloma. The Platform design incorporates a single master protocol, where multiple treatment combinations, as sub-studies, will be evaluated simultaneously.
Recruiting1 award Phase 1 & 211 criteria
More about Ajay K. Nooka, MD,MPH,FACP
Clinical Trial Related6 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Ajay K. Nooka, MD,MPH,FACP has experience with
- Dexamethasone
- Pomalidomide
- Bortezomib
- Belantamab Mafodotin
- Belantamab Mafodotin
- Carfilzomib
Breakdown of trials Ajay K. Nooka, MD,MPH,FACP has run
Multiple Myeloma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ajay K. Nooka, MD,MPH,FACP specialize in?
Ajay K. Nooka, MD,MPH,FACP focuses on Multiple Myeloma and Plasma Cell Neoplasm. In particular, much of their work with Multiple Myeloma has involved t(4;14) positive patients, or patients who are del(17p) positive.
Is Ajay K. Nooka, MD,MPH,FACP currently recruiting for clinical trials?
Yes, Ajay K. Nooka, MD,MPH,FACP is currently recruiting for 2 clinical trials in Atlanta Georgia. If you're interested in participating, you should apply.
Are there any treatments that Ajay K. Nooka, MD,MPH,FACP has studied deeply?
Yes, Ajay K. Nooka, MD,MPH,FACP has studied treatments such as Dexamethasone, Pomalidomide, Bortezomib.
What is the best way to schedule an appointment with Ajay K. Nooka, MD,MPH,FACP?
Apply for one of the trials that Ajay K. Nooka, MD,MPH,FACP is conducting.
What is the office address of Ajay K. Nooka, MD,MPH,FACP?
The office of Ajay K. Nooka, MD,MPH,FACP is located at: Emory Winship Cancer Institute, Atlanta, Georgia 30322 United States. This is the address for their practice at the Emory Winship Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.